Hepa-Gel Lichtenstein

Hepa‑Gel Lichtenstein is a topical heparin sodium preparation, supplied as a gel formulation. It contains heparin sodium as the active ingredient and is marketed in the European Union. The product is intended for cutaneous application and is classified as an anticoagulant. Hepa‑Gel Lichtenstein is used under medical supervision for its antithrombotic properties in specific clinical contexts. It is supplied in single‑use sachets and stored at controlled room temperature.

Hepa‑Gel Lichtenstein is applied to the skin in situations where localized anticoagulation is desired.

- To support the management of superficial thrombophlebitis under physician guidance. - As an adjunct to compression therapy for venous stasis ulcers. - For prophylactic use on surgical incision sites where topical anticoagulation is indicated. - In the treatment of small hematomas or bruises to promote clot resolution. - To assist in the care of catheter insertion sites to reduce clot formation. - When used in combination with systemic anticoagulants, it may provide localized effect while minimizing systemic exposure.

The cutaneous application of heparin sodium may be associated with local and systemic effects, most of which are mild and reversible.

Common: - Minor skin irritation such as redness, itching, or mild rash at the application site. - Transient bruising or discoloration of the skin. - Temporary mild pain or tenderness where the gel is applied. - Localized swelling or edema that resolves after discontinuation. - Mild warmth or tingling sensation at the site of application.

Serious: - Unexpected bleeding or hemorrhage at the site or distant locations. - Development of heparin-induced thrombocytopenia (HIT) characterized by a rapid drop in platelet count. - Allergic reactions including urticaria, angioedema, or anaphylaxis. - Formation of necrotic skin lesions or severe ulceration.

When using Hepa‑Gel Lichtenstein, clinicians should evaluate patient-specific factors and follow standard safety measures to minimize risks.

- Assess for a history of bleeding disorders or recent major surgery before application. - Verify that the patient is not currently receiving high‑dose systemic anticoagulants unless directed by a physician. - Avoid use on open wounds, infected skin, or areas with active dermatitis. - Monitor platelet counts periodically if prolonged topical therapy is planned. - Educate patients to report any unexpected bruising, prolonged bleeding, or signs of allergic reaction promptly. - Store the gel at controlled room temperature and keep the container sealed when not in use.

Heparin sodium applied topically can interact with other agents that affect coagulation or skin integrity, requiring careful assessment.

Avoid: - Concurrent use of other topical anticoagulants or fibrinolytic agents on the same area. - Application over sites where strong irritants or chemical peels have been recently performed.

Use with caution: - Systemic anticoagulant therapy (e.g., warfarin, direct oral anticoagulants) as additive anticoagulant effect may increase bleeding risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) applied locally, which can potentiate bleeding. - Herbal or dietary supplements with anticoagulant properties (e.g., ginkgo, garlic) if used in combination with systemic therapy. - Topical corticosteroids may alter skin absorption of the gel, potentially affecting efficacy.